**7. References**


Alpha-1 Antitrypsin Deficiency – A Genetic Risk Factor for COPD 205

Britigan, B. E., M. B. Hayek, B. N. Doebbeling, and R. B. Fick, Jr. 1993. Transferrin and

Byth, B. C., G. D. Billingsley, and D. W. Cox. 1994. Physical and genetic mapping of the

Campos, M. A., S. Alazemi, G. Zhang, M. Salathe, A. Wanner, R. A. Sandhaus, and H. Baier.

Campos, M. A., S. Alazemi, G. Zhang, R. A. Sandhaus, and A. Wanner. 2008. Influenza vaccination in subjects with alpha1-antitrypsin deficiency. *Chest* 133 (1):49-55. Campos, M. A., S. Alazemi, G. Zhang, A. Wanner, M. Salathe, H. Baier, and R. A. Sandhaus.

Campos, M. A., S. Alazemi, G. Zhang, A. Wanner, and R. A. Sandhaus. 2009. Effects of a

Campos, M. A., A. Wanner, G. Zhang, and R. A. Sandhaus. 2005. Trends in the diagnosis of

Carp, H., F. Miller, J. R. Hoidal, and A. Janoff. 1982. Potential mechanism of emphysema:

Carpenter, M. J., C. Strange, Y. Jones, M. R. Dickson, C. Carter, M. A. Moseley, and G. E.

Carracedo, A., and L. Concheiro. 1983. Distribution of the Pi, TfC, and Gc subtypes in

Carrell, R. W., J. O. Jeppsson, C. B. Laurell, S. O. Brennan, M. C. Owen, L. Vaughan, and D.

Carrell, R. W., and D. A. Lomas. 1997. Conformational disease. *Lancet* 350 (9071):134-8. 2002.

Carroll, T. P., C. M. Greene, C. A. O'Connor, A. M. Nolan, S. J. O'Neill, and N. G.

responses in bronchial epithelial cells. *J Immunol* 175 (11):7594-601.

lungs of patients with cystic fibrosis. *Infect Immun* 61 (12):5049-55.

with alpha 1-antitrypsin deficiency. *Am J Hum Genet* 55 (1):126-33.

deficiency older than 60 years. *Chest* 135 (3):600-8.

augmentation therapy. *Respir Med* 103 (10):1532-9.

Galicia (North West Spain). *Z Rechtsmed* 90 (2):153-8.

(3):703-8.

*COPD* 6 (1):31-40.

*Chest* 128 (3):1179-86.

*Sci U S A* 79 (6):2041-5.

*Med* 33 (1):22-8.

(5872):329-34.

346 (1):45-53.

the common normal and deficient alpha 1-antitrypsin phenotypes. *Chest* 100

lactoferrin undergo proteolytic cleavage in the Pseudomonas aeruginosa-infected

serpin gene cluster at 14q32.1: allelic association and a unique haplotype associated

2009. Clinical characteristics of subjects with symptoms of alpha1-antitrypsin

2009. Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving

disease management program in individuals with alpha-1 antitrypsin deficiency.

symptomatic patients with alpha1-antitrypsin deficiency between 1968 and 2003.

alpha 1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity. *Proc Natl Acad* 

Gilbert. 2007. Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. *Ann Behav* 

R. Boswell. 1982. Structure and variation of human alpha 1-antitrypsin. *Nature* 298

Alpha1-antitrypsin deficiency--a model for conformational diseases. *N Engl J Med*

McElvaney. 2010. Evidence for unfolded protein response activation in monocytes from individuals with alpha-1 antitrypsin deficiency. *J Immunol* 184 (8):4538-46. Carroll, T. P., C. M. Greene, C. C. Taggart, A. G. Bowie, S. J. O'Neill, and N. G. McElvaney.

2005. Viral inhibition of IL-1- and neutrophil elastase-induced inflammatory


American Thoracic Society/European Respiratory Society statement: standards for the

Aslanidis, C., M. Nauck, and G. Schmitz. 1999. High-speed detection of the two common

Barnett, V. T., M. Sekosan, and A. Khurshid. 1999. Wegener's granulomatosis and alpha1-

Bartels, C. L., A. L. Marchetti, W. Edward Highsmith, and G. J. Tsongalis. 2009. Real time

Baur, X., and K. Bencze. 1987. Study of familial alpha-1-proteinase inhibitor deficiency

Beatty, K., J. Bieth, and J. Travis. 1980. Kinetics of association of serine proteinases with

Beckman, L., C. Sikstrom, A. Mikelsaar, A. Krumina, V. Kucinskas, and G. Beckman. 1999.

Belorgey, D., D. C. Crowther, R. Mahadeva, and D. A. Lomas. 2002. Mutant Neuroserpin

Bergin, D. A., E. P. Reeves, P. Meleady, M. Henry, O. J. McElvaney, T. P. Carroll, C.

Bieth, J.G. 1986. Elastases: Catalytic and biological properties. In *Regulation of Matrix* 

Black, L. F., and F. Kueppers. 1978. alpha1-Antitrypsin deficiency in nonsmokers. *Am Rev* 

Blanco, I., E. Fernandez, and E. F. Bustillo. 2001. Alpha-1-antitrypsin PI phenotypes S and Z in Europe: an analysis of the published surveys. *Clin Genet* 60 (1):31-41. Blanco, I., E. Fernandez, M. C. Rodriguez, and A. Fernandez. 1999. [Allelic frequency of the

Bourke, M., M. O'Donovan, F. M. Stevens, and C. F. McCarthy. 1993. Alpha 1-antitrypsin

Brantly M, Mishra V, Zienko L. . 2003. Statewide targeted screening and detection of AAT deficiency. . *American Journal of Respiratory and Critical Care Medicine* 167:A222. Brantly, M. L., J. T. Wittes, C. F. Vogelmeier, R. C. Hubbard, G. A. Fells, and R. G. Crystal.

immune complexes and IL-8. *J Clin Invest* 120 (12):4236-50.

2003. *Am J Respir Crit Care Med* 168 (7):818-900.

and melting curves. *Clin Chem* 45 (10):1872-5.

clinical investigations. *Respiration* 51 (3):188-95.

deficiency. *Am J Transl Res* 1 (4):406-11.

*Biol Chem* 255 (9):3931-4.

(19):17367-73.

Academic Press.

*Respir Dis* 117 (3):421-8.

*Clin (Barc)* 113 (10):366-70.

*Med Sci* 162 (5):171-2.

Sea region. *Hum Hered* 49 (1):52-5.

diagnosis and management of individuals with alpha-1 antitrypsin deficiency.

alpha(1)-antitrypsin deficiency alleles Pi\*Z and Pi\*S by real-time fluorescence PCR

antitrypsin-deficiency emphysema: proteinase-related diseases. *Chest* 116 (1):253-5.

PCR detection of the PI\*Z and PI\*S mutations associated with alpha-1 antitrypsin

including a rare proteinase inhibitor phenotype (IZ). I. Alpha-1-phenotyping and

native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin. *J* 

alpha1-antitrypsin (PI) alleles as markers of Westeuropean influence in the Baltic

(S49P) that causes familial encephalopathy with neuroserpin inclusion bodies is a poor proteinase inhibitor and readily forms polymers in vitro. *J Biol Chem* 277

Condron, S. H. Chotirmall, M. Clynes, S. J. O'Neill, and N. G. McElvaney. 2010. alpha-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble

*Accumulation (Biology of Extracellular Matrix).* edited by R. P. Mecham. New York.:

gene of alpha-1-antitrypsin in the general population in a county in Asturias]. *Med* 

phenotypes in coeliac patients and a control population in the west of Ireland. *Ir J* 

1991. Use of a highly purified alpha 1-antitrypsin standard to establish ranges for

the common normal and deficient alpha 1-antitrypsin phenotypes. *Chest* 100 (3):703-8.


Alpha-1 Antitrypsin Deficiency – A Genetic Risk Factor for COPD 207

de Serres, F. J., I. Blanco, and E. Fernandez-Bustillo. 2010. Ethnic differences in alpha-1

Demeo, D. L., R. A. Sandhaus, A. F. Barker, M. L. Brantly, E. Eden, N. G. McElvaney, S.

DeMeo, D. L., and E. K. Silverman. 2004. Alpha1-antitrypsin deficiency. 2: genetic aspects of

Edmonds, B. K., J. A. Hodge, and R. L. Rietschel. 1991. Alpha 1-antitrypsin deficiency-

Eisner, M. D., N. Anthonisen, D. Coultas, N. Kuenzli, R. Perez-Padilla, D. Postma, I. Romieu,

obstructive pulmonary disease. *Am J Respir Crit Care Med* 182 (5):693-718. Ekeowa, U. I., J. Freeke, E. Miranda, B. Gooptu, M. F. Bush, J. Perez, J. Teckman, C. V.

Ekeowa, U. I., S. J. Marciniak, and D. A. Lomas. 2011. alpha(1)-antitrypsin deficiency and

Elliott, P. R., D. A. Lomas, R. W. Carrell, and J. P. Abrahams. 1996. Inhibitory conformation of the reactive loop of alpha 1-antitrypsin. *Nat Struct Biol* 3 (8):676-81. Eriksson, S. 1964. Pulmonary Emphysema and Alpha1-Antitrypsin Deficiency. *Acta Med* 

Faber, J. P., W. Poller, S. Weidinger, M. Kirchgesser, R. Schwaab, F. Bidlingmaier, and K.

Fagerhol, M. K., and M. Braend. 1965. Serum prealbumin: polymorphism in man. *Science* 149

Fagerhol, M. K., and C. B. Laurell. 1970. The Pi system-inherited variants of serum alpha 1-

Ferrarotti, I., J. Baccheschi, M. Zorzetto, C. Tinelli, L. Corda, B. Balbi, I. Campo, E. Pozzi, G.

Ferrarotti, I., M. Zorzetto, R. Scabini, P. Mazzola, I. Campo, and M. Luisetti. 2004. A novel

Fick, R. B., Jr., G. P. Naegel, S. U. Squier, R. E. Wood, J. B. Gee, and H. Y. Reynolds. 1984.

Olek. 1994. Identification and DNA sequence analysis of 15 new alpha 1-antitrypsin variants, including two PI\*Q0 alleles and one deficient PI\*M allele. *Am J Hum Genet*

Faa, P. Coni, G. Massi, G. Stella, and M. Luisetti. 2005. Prevalence and phenotype of subjects carrying rare variants in the Italian registry for alpha1-antitrypsin

method for rapid genotypic identification of alpha 1-antitrypsin variants. *Diagn Mol* 

Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. *J Clin Invest* 74 (1):236-48.

serpinopathies. *Proc Natl Acad Sci U S A* 107 (40):17146-51.

inflammation. *Expert Rev Clin Immunol* 7 (2):243-52.

alpha-1-antitrypsin deficiency. *Thorax* 62 (9):806-13.

risk. *Thorax* 59 (3):259-64.

70.

(4):296-9.

*Scand* 175:197-205.

55 (6):1113-21.

(3687):986-7.

*Pathol* 13 (3):160-3.

antitrypsin. *Prog Med Genet* 7:96-111.

deficiency. *J Med Genet* 42 (3):282-7.

antitrypsin deficiency in the United States of America. *Ther Adv Respir Dis* 4 (2):63-

Rennard, E. Burchard, J. M. Stocks, J. K. Stoller, C. Strange, G. M. Turino, E. J. Campbell, and E. K. Silverman. 2007. Determinants of airflow obstruction in severe

alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema

associated panniculitis: case report and review of the literature. *Pediatr Dermatol* 8

E. K. Silverman, and J. R. Balmes. 2010. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic

Robinson, and D. A. Lomas. 2010. Defining the mechanism of polymerization in the


Carroll, T. P., C. A. O'Connor, O. Floyd, J. McPartlin, D. P. Kelleher, G. O'Brien, B. D.

Carroll, T.P., N.G. McElvaney, and C.M. Greene. 2010. Gain of Function Effects of Z Alpha-1

Celli, B. R., and W. MacNee. 2004. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J* 23 (6):932-46. Chapman, K. R., R. A. Stockley, C. Dawkins, M. M. Wilkes, and R. J. Navickis. 2009.

Chen, Y., M. R. Snyder, Y. Zhu, L. J. Tostrud, L. M. Benson, J. A. Katzmann, and H. R.

Cichy, J., J. Potempa, and J. Travis. 1997. Biosynthesis of alpha1-proteinase inhibitor by

Cook, L., J. G. Burdon, S. Brenton, K. R. Knight, and E. D. Janus. 1996. Kinetic

Costa, X., R. Jardi, F. Rodriguez, M. Miravitlles, M. Cotrina, C. Gonzalez, C. Pascual, and R.

Cox, D. W., A. M. Johnson, and M. K. Fagerhol. 1980. Report of Nomenclature Meeting for

Cox, D. W., S. L. Woo, and T. Mansfield. 1985. DNA restriction fragments associated with

Curiel, D. T., A. Chytil, M. Courtney, and R. G. Crystal. 1989. Serum alpha 1-antitrypsin

Dabbagh, K., G. J. Laurent, A. Shock, P. Leoni, J. Papakrivopoulou, and R. C. Chambers.

Dahl, M., C. P. Hersh, N. P. Ly, C. S. Berkey, E. K. Silverman, and B. G. Nordestgaard. 2005.

Davis, R. L., A. E. Shrimpton, P. D. Holohan, C. Bradshaw, D. Feiglin, G. H. Collins, P.

human lung-derived epithelial cells. *J Biol Chem* 272 (13):8250-5.

dried blood spot specimens. *Eur Respir J* 15 (6):1111-5.

mutant neuroserpin. *Nature* 401 (6751):376-9.

of alpha-1 antitrypsin deficiency in Ireland. *Respir Res* 12 (1):91.

(4):336-346.

(3):177-84.

(8):1161-8.

33.

(6023):79-81.

264 (18):10477-86.

186 (1):73-81.

76.

elastase. *Pathology* 28 (3):242-7.

Dimitrov, V. B. Morris, C. C. Taggart, and N. G. McElvaney. 2011. The prevalence

Antitrypsin. *Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry* 9

Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. *COPD* 6

Bergen, 3rd. 2011. Simultaneous Phenotyping and Quantification of {alpha}-1- Antitrypsin by Liquid Chromatography-Tandem Mass Spectrometry. *Clin Chem* 57

characterisation of alpha-1-antitrypsin F as an inhibitor of human neutrophil

Vidal. 2000. Simple method for alpha1-antitrypsin deficiency screening by use of

alpha 1-antitrypsin, INSERM, Rouen/Bois-Guillaume-1978. *Hum Genet* 53 (3):429-

alpha 1-antitrypsin indicate a single origin for deficiency allele PI Z. *Nature* 316

deficiency associated with the common S-type (Glu264----Val) mutation results from intracellular degradation of alpha 1-antitrypsin prior to secretion. *J Biol Chem*

2001. Alpha-1-antitrypsin stimulates fibroblast proliferation and procollagen production and activates classical MAP kinase signalling pathways. *J Cell Physiol*

The protease inhibitor PI\*S allele and COPD: a meta-analysis. *Eur Respir J* 26 (1):67-

Sonderegger, J. Kinter, L. M. Becker, F. Lacbawan, D. Krasnewich, M. Muenke, D. A. Lawrence, M. S. Yerby, C. M. Shaw, B. Gooptu, P. R. Elliott, J. T. Finch, R. W. Carrell, and D. A. Lomas. 1999. Familial dementia caused by polymerization of


Alpha-1 Antitrypsin Deficiency – A Genetic Risk Factor for COPD 209

Guyot, N., M. W. Butler, P. McNally, S. Weldon, C. M. Greene, R. L. Levine, S. J. O'Neill, C.

Hackbarth, J. S., L. J. Tostrud, K. M. Rumilla, M. J. Krowka, and M. R. Snyder. 2010.

Hersh, C. P., M. Dahl, N. P. Ly, C. S. Berkey, B. G. Nordestgaard, and E. K. Silverman. 2004.

Hirche, T. O., E. C. Crouch, M. Espinola, T. J. Brokelman, R. P. Mecham, N. DeSilva, J.

Holme, J., and R. A. Stockley. 2009. CT scan appearance, densitometry, and health status in protease inhibitor SZ alpha1-antitrypsin deficiency. *Chest* 136 (5):1284-90. Hoogendoorn, M., T. L. Feenstra, R. T. Hoogenveen, M. Al, and M. R. Molken. 2010.

Hu, C., and D. H. Perlmutter. 2002. Cell-specific involvement of HNF-1beta in alpha(1)-

Hubbard, R. C., F. Ogushi, G. A. Fells, A. M. Cantin, S. Jallat, M. Courtney, and R. G.

ineffective as an inhibitor of neutrophil elastase. *J Clin Invest* 80 (5):1289-95. Huntington, J. A., R. J. Read, and R. W. Carrell. 2000. Structure of a serpin-protease complex

Hutchison, D. C. 1998. Alpha 1-antitrypsin deficiency in Europe: geographical distribution

Hutchison, D. C., M. J. Tobin, and P. J. Cook. 1983. Alpha 1 antitrypsin deficiency: clinical

Jack, C. I., and C. C. Evans. 1991. Three cases of alpha-1-antitrypsin deficiency in the elderly.

Jacobsson, K. 1955. I. Studies on the determination of fibrinogen in human blood plasma. II.

Janoff, A., and H. Carp. 1977. Possible mechanisms of emphysema in smokers: cigarette

shows inhibition by deformation. *Nature* 407 (6806):923-6.

of Pi types S and Z. *Respir Med* 92 (3):367-77.

Thoracic Association. *Br J Dis Chest* 77 (1):28-34.

cystic fibrosis. *J Biol Chem* 283 (47):32377-85.

patient. *Clin Chim Acta* 411 (15-16):1146-8. Halpin, D. 2004. NICE guidance for COPD. *Thorax* 59 (3):181-2.

1-antitrypsin deficiency. *Chest* 133 (4):981-8.

COPD. *Int J Chron Obstruct Pulmon Dis* 5:435-44.

*Cell Mol Physiol* 282 (4):L757-65.

*Postgrad Med J* 67 (791):840-2.

*Lab Invest* 7 (Suppl. 14):3-102.

(1):65-72.

a meta-analysis. *Thorax* 59 (10):843-9.

C. Taggart, and N. G. McElvaney. 2008. Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with

Discordant alpha-1 antitrypsin phenotype and genotype results in a liver transplant

Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes:

Cooley, E. Remold-O'Donnell, and A. Belaaouaj. 2004. Neutrophil serine proteinases inactivate surfactant protein D by cleaving within a conserved subregion of the carbohydrate recognition domain. *J Biol Chem* 279 (26):27688-98. Hogarth, D. K., and G. Rachelefsky. 2008. Screening and familial testing of patients for alpha

Association between lung function and exacerbation frequency in patients with

antitrypsin gene expression in human respiratory epithelial cells. *Am J Physiol Lung* 

Crystal. 1987. Oxidants spontaneously released by alveolar macrophages of cigarette smokers can inactivate the active site of alpha 1-antitrypsin, rendering it

and physiological features in heterozygotes of Pi type SZ. A survey by the British

Studies on the trypsin and plasmin inhibitors in human blood serum. *Scand J Clin* 

smoke condensate suppresses protease inhibition in vitro. *Am Rev Respir Dis* 116


Fischer, B. M., and J. A. Voynow. 2002. Neutrophil elastase induces MUC5AC gene

Fregonese, L., J. Stolk, R. R. Frants, and B. Veldhuisen. 2008. Alpha-1 antitrypsin Null

Fromer, L. 2010. Improving diagnosis and management of alpha-1 antitrypsin deficiency in

Fromer, L., and C. B. Cooper. 2008. A review of the GOLD guidelines for the diagnosis and

Geraghty, P., M. P. Rogan, C. M. Greene, R. M. Boxio, T. Poiriert, M. O'Mahony, A.

Geraghty, P., M. P. Rogan, C. M. Greene, M. L. Brantly, S. J. O'Neill, C. C. Taggart, and N. G.

Gettins, P. G. 2002. Serpin structure, mechanism, and function. *Chem Rev* 102 (12):4751-804. Gishen, P., A. J. Saunders, M. J. Tobin, and D. C. Hutchison. 1982. Alpha 1-antitrypsin

Gooptu, B., B. Hazes, W. S. Chang, T. R. Dafforn, R. W. Carrell, R. J. Read, and D. A. Lomas.

Gooptu, B., and D. A. Lomas. 2009. Conformational pathology of the serpins: themes,

Graham, A., N. A. Kalsheker, C. R. Newton, F. J. Bamforth, S. J. Powell, and A. F. Markham.

Greene, C. M., and N. G. McElvaney. 2010. Protein misfolding and obstructive lung disease.

Greene, C. M., S. D. Miller, T. Carroll, C. McLean, M. O'Mahony, M. W. Lawless, S. J.

Gross, P., E. A. Pfitzer, E. Tolker, M. A. Babyak, and M. Kaschak. 1965. Experimental

conformational disease. *Proc Natl Acad Sci U S A* 97 (1):67-72.

and PiI (Arg39----Cys). *Hum Genet* 84 (1):55-8.

*Proc Am Thorac Soc* 7 (6):346-55.

*Metab Dis* 31 (1):21-34.

*Health* 11:50-8.

variations, and therapeutic strategies. *Annu Rev Biochem* 78:147-76.

mutations and severity of emphysema. *Respir Med* 102 (6):876-84.

primary care: translating knowledge into action. *COPD* 7 (3):192-8.

treatment of patients with COPD. *Int J Clin Pract* 62 (8):1219-36. Gadek, J. E. 1992. Adverse effects of neutrophils on the lung. *Am J Med* 92 (6A):27S-31S. Gadek, J. E., G. A. Fells, and R. G. Crystal. 1979. Cigarette smoking induces functional

*Am J Respir Cell Mol Biol* 26 (4):447-52.

(4424):1315-6.

(4):371-7.

*Immunol* 178 (9):5871-8.

in vivo and in vitro. *Thorax* 63 (7):621-6.

expression in airway epithelium via a pathway involving reactive oxygen species.

antiprotease deficiency in the lower respiratory tract of humans. *Science* 206

Belaaouaj, S. J. O'Neill, C. C. Taggart, and N. G. McElvaney. 2007. Neutrophil elastase up-regulates cathepsin B and matrix metalloprotease-2 expression. *J* 

McElvaney. 2008. Alpha-1-antitrypsin aerosolised augmentation abrogates neutrophil elastase-induced expression of cathepsin B and matrix metalloprotease 2

deficiency: the radiological features of pulmonary emphysema in subjects of Pi type Z and Pi type SZ: a survey by the British Thoracic Association. *Clin Radiol* 33

2000. Inactive conformation of the serpin alpha(1)-antichymotrypsin indicates twostage insertion of the reactive loop: implications for inhibitory function and

1989. Molecular characterisation of three alpha-1-antitrypsin deficiency variants: proteinase inhibitor (Pi) nullcardiff (Asp256----Val); PiMmalton (Phe51----deletion)

O'Neill, C. C. Taggart, and N. G. McElvaney. 2008. Alpha-1 antitrypsin deficiency: a conformational disease associated with lung and liver manifestations. *J Inherit* 

Emphysema: Its Production with Papain in Normal and Silicotic Rats. *Arch Environ* 


Alpha-1 Antitrypsin Deficiency – A Genetic Risk Factor for COPD 211

Law, R. H., Q. Zhang, S. McGowan, A. M. Buckle, G. A. Silverman, W. Wong, C. J. Rosado,

Lee, J. H., and M. Brantly. 2000. Molecular mechanisms of alpha1-antitrypsin null alleles.

Lewis, M., J. Kallenbach, M. Zaltzman, H. Levy, D. Lurie, R. Baynes, P. King, and A. Meyers.

rapidly progressive glomerulonephritis, and colitis. *Am J Med* 79 (4):489-94. Lieberman, J., C. Mittman, and H. W. Gordon. 1972. Alpha 1 antitrypsinin the livers of

Lieberman, J., B. Winter, and A. Sastre. 1986. Alpha 1-antitrypsin Pi-types in 965 COPD

Lomas, D. A. 2006. The selective advantage of alpha1-antitrypsin deficiency. *Am J Respir Crit* 

Lomas, D. A., D. L. Evans, J. T. Finch, and R. W. Carrell. 1992. The mechanism of Z alpha 1-

Lomas, D. A., and R. Mahadeva. 2002. Alpha1-antitrypsin polymerization and the

Luisetti, M., and N. Seersholm. 2004. Alpha1-antitrypsin deficiency. 1: epidemiology of

Mahadeva, R., C. Atkinson, Z. Li, S. Stewart, S. Janciauskiene, D. G. Kelley, J. Parmar, R.

Mahadeva, R., W. S. Chang, T. R. Dafforn, D. J. Oakley, R. C. Foreman, J. Calvin, D. G.

Malerba, M., F. Ricciardolo, A. Radaeli, C. Torregiani, L. Ceriani, E. Mori, M. Bontempelli, C.

Malfait, R., F. Gorus, and C. Sevens. 1985. Electrophoresis of serum protein to detect alpha 1 antitrypsin deficiency: five illustrative cases. *Clin Chem* 31 (8):1397-9. Mannino, D. M., and S. Braman. 2007. The epidemiology and economics of chronic

Mannino, D. M., R. C. Gagnon, T. L. Petty, and E. Lydick. 2000. Obstructive lung disease and

Nutrition Examination Survey, 1988-1994. *Arch Intern Med* 160 (11):1683-9. Matsunaga, E., S. Shiokawa, H. Nakamura, T. Maruyama, K. Tsuda, and Y. Fukumaki. 1990.

Mayer, A. S., J. K. Stoller, S. Vedal, A. J. Ruttenber, M. Strand, R. A. Sandhaus, and L. S.

serpinopathies: pathobiology and prospects for therapy. *J Clin Invest* 110 (11):1585-

Pitman, S. D. Shapiro, and D. A. Lomas. 2005. Polymers of Z alpha1-antitrypsin colocalize with neutrophils in emphysematous alveoli and are chemotactic in vivo.

Wight, and D. A. Lomas. 1999. Heteropolymerization of S, I, and Z alpha1-

Tantucci, and V. Grassi. 2006. Neutrophilic inflammation and IL-8 levels in induced

low lung function in adults in the United States: data from the National Health and

Molecular analysis of the gene of the alpha 1-antitrypsin deficiency variant,

Newman. 2006. Risk factors for symptom onset in PI\*Z alpha-1 antitrypsin

antitrypsin accumulation in the liver. *Nature* 357 (6379):605-7.

antitrypsin and liver cirrhosis. *J Clin Invest* 103 (7):999-1006.

sputum of alpha-1-antitrypsin PiMZ subjects. *Thorax* 61 (2):129-33.

obstructive pulmonary disease. *Proc Am Thorac Soc* 4 (7):502-6.

Mnichinan. *Am J Hum Genet* 46 (3):602-12.

deficiency. *Int J Chron Obstruct Pulmon Dis* 1 (4):485-92.

the serpin superfamily. *Genome Biol* 7 (5):216.

patients with emphysema. *Science* 175 (17):63-5.

alpha1-antitrypsin deficiency. *Thorax* 59 (2):164-9.

*Respir Med* 94 Suppl C:S7-11.

patients. *Chest* 89 (3):370-3.

*Care Med* 173 (10):1072-7.

*Am J Pathol* 166 (2):377-86.

90.

C. G. Langendorf, R. N. Pike, P. I. Bird, and J. C. Whisstock. 2006. An overview of

1985. Severe deficiency of alpha 1-antitrypsin associated with cutaneous vasculitis,


Janoff, A., and J. Scherer. 1968. Mediators of inflammation in leukocyte lysosomes. IX.

Jeppsson, J. O., C. B. Laurell, B. Nosslin, and D. W. Cox. 1978. Catabolic rate of alpha1-

Jeschke, M. G., R. E. Barrow, and D. N. Herndon. 2004. Extended hypermetabolic response of the liver in severely burned pediatric patients. *Arch Surg* 139 (6):641-7. Johnson, D., and J. Travis. 1979. The oxidative inactivation of human alpha-1-proteinase

Jones, E. A., J. Vergalla, C. J. Steer, P. R. Bradley-Moore, and J. M. Vierling. 1978. Metabolism of intact and desialylated alpha 1-antitrypsin. *Clin Sci Mol Med* 55 (2):139-48. Kelly, C. P., D. N. Tyrrell, G. S. McDonald, D. B. Whitehouse, and J. S. Prichard. 1989.

King, M. A., J. A. Stone, P. T. Diaz, C. F. Mueller, W. J. Becker, and J. E. Gadek. 1996. Alpha

Knoell, D. L., D. R. Ralston, K. R. Coulter, and M. D. Wewers. 1998. Alpha 1-antitrypsin and

Kohnlein, T., S. Janciauskiene, and T. Welte. 2010. Diagnostic delay and clinical modifiers in

Kohri, K., I. F. Ueki, and J. A. Nadel. 2002. Neutrophil elastase induces mucin production by

Kok, K. F., H. L. Willems, and J. P. Drenth. 2010. The cut-off value of 100 mg/dl is

Kossmann, T., V. H. Hans, H. G. Imhof, R. Stocker, P. Grob, O. Trentz, and C. Morganti-

Koulmanda, M., M. Bhasin, L. Hoffman, Z. Fan, A. Qipo, H. Shi, S. Bonner-Weir, P. Putheti,

autoimmune diabetic NOD mice. *Proc Natl Acad Sci U S A* 105 (42):16242-7. Kubba, A. K., and M. Young. 1998. The long suffering of Frederic Chopin. *Chest* 113 (1):210-6. Kueppers, F. 1971. Alpha-1-antitrypsin: physiology, genetics and pathology. *Humangenetik*

Laurell, C.B., and S.E. Eriksson. 1963. The electrophoretic alpha-globulin pattern of serum in

alpha1-antitrypsin deficiency. *Scand. J. Clin. Lab. Invest.* 15:132-140.

in patients with severe traumatic brain injuries. *Shock* 4 (5):311-7.

Kuzemko, J. A. 1994. Chopin's illnesses. *J R Soc Med* 87 (12):769-72.

alpha-1 antitrypsin deficiency. *Ther Adv Respir Dis* 4 (5):279-87.

*Cell Mol Physiol* 283 (3):L531-40.

patients. *Liver Int* 30 (3):491-2.

11 (3):177-89.

and hepatic disease: case report and family study. *Thorax* 44 (9):758-9. Kim, W. D., D. H. Eidelman, J. L. Izquierdo, H. Ghezzo, M. P. Saetta, and M. G. Cosio. 1991.

and functional entities. *Am Rev Respir Dis* 144 (6):1385-90.

*Med* 128 (5):1137-55.

(10):4022-6.

41.

*Sci Mol Med* 55 (1):103-7.

Elastinolytic activity in granules of human polymorphonuclear leukocytes. *J Exp* 

antitrypsin of of Pi types S, and MMalton and of asialylated M-protein in man. *Clin* 

inhibitor. Further evidence for methionine at the reactive center. *J Biol Chem* 254

Heterozygous FZ alpha 1 antitrypsin deficiency associated with severe emphysema

Centrilobular and panlobular emphysema in smokers. Two distinct morphologic

1-antitrypsin deficiency: evaluation of bronchiectasis with CT. *Radiology* 199 (1):137-

protease complexation is induced by lipopolysaccharide, interleukin-1beta, and tumor necrosis factor-alpha in monocytes. *Am J Respir Crit Care Med* 157 (1):246-55.

ligand-dependent epidermal growth factor receptor activation. *Am J Physiol Lung* 

insufficient to detect heterozygous alpha-1 antitrypsin-deficient liver disease

Kossmann. 1995. Intrathecal and serum interleukin-6 and the acute-phase response

N. Degauque, T. A. Libermann, H. Auchincloss, Jr., J. S. Flier, and T. B. Strom. 2008. Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in


Alpha-1 Antitrypsin Deficiency – A Genetic Risk Factor for COPD 213

Parr, D. G., P. G. Guest, J. H. Reynolds, L. J. Dowson, and R. A. Stockley. 2007. Prevalence

Parr, D. G., B. C. Stoel, J. Stolk, and R. A. Stockley. 2004. Pattern of emphysema distribution

Perlmutter, D. H., J. D. Daniels, H. S. Auerbach, K. De Schryver-Kecskemeti, H. S. Winter,

Petrache, I., I. Fijalkowska, T. R. Medler, J. Skirball, P. Cruz, L. Zhen, H. I. Petrache, T. R.

Piitulainen, E., G. Tornling, and S. Eriksson. 1997. Effect of age and occupational exposure to

Rahaghi, F., I. Ortega, N. Rahaghi, E. Oliveira, J. Ramirez, L. Smolley, and J. K. Stoller. 2009.

Rodriguez-Frias, F., B. Vila-Auli, M. Homs-Riba, R. Vidal-Pla, J. L. Calpe-Calpe, and R.

Rogers, J., N. Kalsheker, S. Wallis, A. Speer, C. H. Coutelle, D. Woods, and S. E. Humphries.

Sandford, A. J., T. Chagani, J. J. Spinelli, and P. D. Pare. 1999. alpha1-antitrypsin genotypes

Santos Rosa, M. A., and A. J. Robalo Cordeiro. 1986. Alpha-1-proteinase inhibitor phenotypes in Portuguese population. *Eur J Respir Dis Suppl* 146:167-73. Schultze, H. E., K. Heide, and H. Haupt. 1962. [alpha1-Antitrypsin from human serum]. *Klin* 

Rapid Diagnostic Laboratory Tests. *Arch Bronconeumol* 47 (8):415-417. Rodriguez, F., R. Jardi, X. Costa, M. Cotrina, R. Galimany, R. Vidal, and M. Miravitlles. 2002.

preventing lung endothelial cell apoptosis. *Am J Pathol* 169 (4):1155-66. Petrache, I., I. Fijalkowska, L. Zhen, T. R. Medler, E. Brown, P. Cruz, K. H. Choe, L.

intestinal epithelial cell line. *J Biol Chem* 264 (16):9485-90.

Rada, A. G. 2010. Spain votes to ban smoking in public places. *BMJ* 341:c7429.

function test (PFT) results. *COPD* 6 (1):26-30.

*Med* 176 (12):1215-21.

173 (11):1222-8.

*Med* 166 (6):814-7.

(5 Pt 1):1624-8.

*Wochenschr* 40:427-9.

*Commun* 116 (2):375-82.

*Crit Care Med* 170 (11):1172-8.

(PiZZ). *Thorax* 53 (11):939-43.

and impact of bronchiectasis in alpha1-antitrypsin deficiency. *Am J Respir Crit Care* 

in alpha1-antitrypsin deficiency influences lung function impairment. *Am J Respir* 

and D. H. Alpers. 1989. The alpha 1-antitrypsin gene is expressed in a human

Flotte, and R. M. Tuder. 2006. alpha-1 antitrypsin inhibits caspase-3 activity,

Taraseviciene-Stewart, R. Scerbavicius, L. Shapiro, B. Zhang, S. Song, D. Hicklin, N. F. Voelkel, T. Flotte, and R. M. Tuder. 2006. A novel antiapoptotic role for alpha1 antitrypsin in the prevention of pulmonary emphysema. *Am J Respir Crit Care Med*

airway irritants on lung function in non-smoking individuals with alpha 1 antitrypsin deficiency (PiZZ). *Thorax* 52 (3):244-8. 1998. Environmental correlates of impaired lung function in non-smokers with severe alpha 1-antitrypsin deficiency

Physician alert suggesting alpha-1 antitrypsin deficiency testing in pulmonary

Jardi-Margalef. 2011. Diagnosis of Alpha-1 Antitrypsin Deficiency: Limitations of

Rapid screening for alpha1-antitrypsin deficiency in patients with chronic obstructive pulmonary disease using dried blood specimens. *Am J Respir Crit Care* 

1983. The isolation of a clone for human alpha 1-antitrypsin and the detection of alpha 1-antitrypsin in mRNA from liver and leukocytes. *Biochem Biophys Res* 

and the acute-phase response to open heart surgery. *Am J Respir Crit Care Med* 159


McCarthy, C., and B. D. Dimitrov. 2010. Augmentation therapy for alpha-1 antitrypsin

McElvaney, N. G. 2004. Smoking ban--made in Ireland, for home use and for export. *N Engl* 

McElvaney, N. G., J. K. Stoller, A. S. Buist, U. B. Prakash, M. L. Brantly, M. D. Schluchter,

Miravitlles, M., C. Herr, I. Ferrarotti, R. Jardi, F. Rodriguez-Frias, M. Luisetti, and R. Bals.

Miravitlles, M., S. Vila, M. Torrella, E. Balcells, F. Rodriguez-Frias, C. de la Roza, R. Jardi,

Mornex, J. F., A. Chytil-Weir, Y. Martinet, M. Courtney, J. P. LeCocq, and R. G. Crystal. 1986.

and alpha-1-antitrypsin-deficient individuals. *J Clin Invest* 77 (6):1952-61. Mulgrew, A. T., C. C. Taggart, M. W. Lawless, C. M. Greene, M. L. Brantly, S. J. O'Neill, and

National Heart, Lung, and Blood Institute. 2009. Morbidity and Mortality: 2009 Chart Book

Needham, M., and R. A. Stockley. 2005. Exacerbations in {alpha}1-antitrypsin deficiency. *Eur* 

Ogushi, F., G. A. Fells, R. C. Hubbard, S. D. Straus, and R. G. Crystal. 1987. Z-type alpha 1-

Ogushi, F., R. C. Hubbard, G. A. Fells, M. A. Casolaro, D. T. Curiel, M. L. Brantly, and R. G.

Parmar, J. S., R. Mahadeva, B. J. Reed, N. Farahi, K. A. Cadwallader, M. T. Keogan, D. Bilton,

vitro inhibitor of neutrophil elastase. *Am Rev Respir Dis* 137 (2):364-70. Okayama, H., M. Brantly, M. Holmes, and R. G. Crystal. 1991. Characterization of the molecular basis of the alpha 1-antitrypsin F allele. *Am J Hum Genet* 48 (6):1154-8. Owen, M. C., S. O. Brennan, J. H. Lewis, and R. W. Carrell. 1983. Mutation of antitrypsin to

characteristics and severity of asthma in adults. *Respir Med* 96 (3):186-92. Modrykamien, A., and J. K. Stoller. 2009. Alpha-1 antitrypsin (AAT) deficiency - what are

the treatment options? *Expert Opin Pharmacother* 10 (16):2653-61.

Antitrypsin Deficiency Registry Study Group. *Chest* 111 (2):394-403. McGee, D., L. Schwarz, R. McClure, L. Peterka, F. Rouhani, M. Brantly, and C. Strange. 2010.

three European centres. *Eur Respir J* 35 (5):960-8.

neutrophil chemoattractant. *Chest* 125 (5):1952-7.

on Cardiovascular, Lung, and Blood Diseases. .

neutrophil elastase. *J Clin Invest* 80 (5):1366-74.

bleeding disorder. *N Engl J Med* 309 (12):694-8.

emphysema. *Am J Respir Cell Mol Biol* 26 (6):723-30.

*Respir J* 25 (6):992-1000.

reply 235-6.

2010:570679.

*J Med* 350 (22):2231-3.

deficiency--not enough evidence to support its use yet! *COPD* 7 (3):234; author

and R. D. Crystal. 1997. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-

Is PiSS Alpha-1 Antitrypsin Deficiency Associated with Disease? *Pulm Med*

2010. Laboratory testing of individuals with severe alpha1-antitrypsin deficiency in

and R. Vidal. 2002. Influence of deficient alpha1-anti-trypsin phenotypes on clinical

Expression of the alpha-1-antitrypsin gene in mononuclear phagocytes of normal

N. G. McElvaney. 2004. Z alpha1-antitrypsin polymerizes in the lung and acts as a

antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of

Crystal. 1988. Evaluation of the S-type of alpha-1-antitrypsin as an in vivo and in

antithrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal

E. R. Chilvers, and D. A. Lomas. 2002. Polymers of alpha(1)-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of


Alpha-1 Antitrypsin Deficiency – A Genetic Risk Factor for COPD 215

Stoller, J. K., and L. S. Aboussouan. 2004. alpha1-Antitrypsin deficiency . 5: intravenous

Stoller, J. K., L. Fromer, M. Brantly, J. Stocks, and C. Strange. 2007. Primary care diagnosis of

Stoller, J. K., R. A. Sandhaus, G. Turino, R. Dickson, K. Rodgers, and C. Strange. 2005. Delay

Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The

Sveger, T. 1976. Liver disease in alpha1-antitrypsin deficiency detected by screening of

Taggart, C. C., C. M. Greene, T. P. Carroll, S. J. O'Neill, and N. G. McElvaney. 2005.

Tanash, H. A., P. M. Nilsson, J. A. Nilsson, and E. Piitulainen. 2008. Clinical course and

Tosi, M. F., H. Zakem, and M. Berger. 1990. Neutrophil elastase cleaves C3bi on opsonized

Townley, R. G., J. G. Southard, P. Radford, R. J. Hopp, A. K. Bewtra, and L. Ford. 1990.

Travis, J., and G. S. Salvesen. 1983. Human plasma proteinase inhibitors. *Annu Rev Biochem*

Turino, G. M., A. F. Barker, M. L. Brantly, A. B. Cohen, R. P. Connelly, R. G. Crystal, E. Eden,

Viedma, J. A., A. de la Iglesia, M. Parera, and M. T. Lopez. 1986. A new automated

Voulgari, F., P. Cummins, T. I. Gardecki, N. J. Beeching, P. C. Stone, and J. Stuart. 1982.

Weldon, S., P. McNally, N. G. McElvaney, J. S. Elborn, D. F. McAuley, J. Wartelle, A.

Registry Study Group. *Am J Respir Crit Care Med* 154 (6 Pt 1):1718-25. Venembre, P., A. Boutten, N. Seta, M. S. Dehoux, B. Crestani, M. Aubier, and G. Durand.

infective lung disease. *Am J Respir Crit Care Med* 171 (10):1070-6.

*Radiol Med* 109 (1-2):27-39.

(6):546-50.

(12):869-74.

(4):1989-94.

*Med* 158 (1):49-59.

*Respir Res* 11:44.

52:655-709.

3):171-4.

32 (6):1020-2.

200,000 infants. *N Engl J Med* 294 (24):1316-21.

opsonin receptor mismatch. *J Clin Invest* 86 (1):300-8.

surgery, and infection. *Br Heart J* 48 (4):352-6.

Correlations between high resolution dynamic CT and pulmonary function testing.

augmentation therapy: current understanding. *Thorax* 59 (8):708-12. 2009. Myths and misconceptions about {alpha}1-antitrypsin deficiency. *Arch Intern Med* 169

alpha-1 antitrypsin deficiency: issues and opportunities. *Cleve Clin J Med* 74

in diagnosis of alpha1-antitrypsin deficiency: a continuing problem. *Chest* 128

Alpha-1-Antitrypsin Deficiency Registry Study Group. 1998. *Am J Respir Crit Care* 

Elastolytic proteases: inflammation resolution and dysregulation in chronic

prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ). *Thorax* 63 (12):1091-5. 2010. Survival in severe alpha-1-antitrypsin deficiency (PiZZ).

pseudomonas as well as CR1 on neutrophils to create a functionally important

Association of MS Pi phenotype with airway hyperresponsiveness. *Chest* 98 (3):594-9.

M. D. Schluchter, and J. K. Stoller. 1996. Clinical features of individuals with PI\*SZ phenotype of alpha 1-antitrypsin deficiency. alpha 1-Antitrypsin Deficiency

1994. Secretion of alpha 1-antitrypsin by alveolar epithelial cells. *FEBS Lett* 346 (2-

turbidimetric immunoassay for quantifying alpha 1-antitrypsin in serum. *Clin Chem*

Serum levels of acute phase and cardiac proteins after myocardial infarction,

Belaaouaj, R. L. Levine, and C. C. Taggart. 2009. Decreased levels of secretory


Seemungal, T. A., G. C. Donaldson, E. A. Paul, J. C. Bestall, D. J. Jeffries, and J. A. Wedzicha.

Seersholm, N., and A. Kok-Jensen. 1995. Survival in relation to lung function and smoking

pulmonary disease. *Am J Respir Crit Care Med* 157 (5 Pt 1):1418-22.

1):2119-26.

*Med* 73 (6):934-9.

*Biol Chem* 276 (36):33293-6.

275 (43):33663-8.

*Chem* 52 (12):2236-42.

(5):1125-32.

1998. Effect of exacerbation on quality of life in patients with chronic obstructive

cessation in patients with severe hereditary alpha 1-antitrypsin deficiency. *Am J Respir Crit Care Med* 151 (2 Pt 1):369-73. 1998. Intermediate alpha 1-antitrypsin deficiency PiSZ: a risk factor for pulmonary emphysema? *Respir Med* 92 (2):241-5. Seersholm, N., A. Kok-Jensen, and A. Dirksen. 1994. Survival of patients with severe alpha 1 antitrypsin deficiency with special reference to non-index cases. *Thorax* 49 (7):695-8. Seixas, S., O. Garcia, M. J. Trovoada, M. T. Santos, A. Amorim, and J. Rocha. 2001. Patterns

of haplotype diversity within the serpin gene cluster at 14q32.1: insights into the natural history of the alpha1-antitrypsin polymorphism. *Hum Genet* 108 (1):20-30. Seyama, K., T. Nukiwa, S. Souma, K. Shimizu, and S. Kira. 1995. Alpha 1-antitrypsin-

deficient variant Siiyama (Ser53[TCC] to Phe53[TTC]) is prevalent in Japan. Status of alpha 1-antitrypsin deficiency in Japan. *Am J Respir Crit Care Med* 152 (6 Pt

1-antitrypsin deficiency: a previously unrecognized inherited disorder. *J Lab Clin* 

diffusing capacity of the lung for carbon monoxide in community subjects with the

Irving, D. A. Lomas, C. J. Luke, R. W. Moyer, P. A. Pemberton, E. Remold-O'Donnell, G. S. Salvesen, J. Travis, and J. C. Whisstock. 2001. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. *J* 

antitrypsin polymers are formed by reactive loop-beta-sheet A linkage. *J Biol Chem*

of the detection of the alpha1-antitrypsin "Z" deficiency variant by routine serum

W. E. Highsmith, and S. N. Thibodeau. 2006. Diagnosis of alpha-1-antitrypsin deficiency: An algorithm of quantification, genotyping, and phenotyping. *Clin* 

Campbell, A. Agusti, P. M. Calverley, C. F. Donner, B. J. Make, S. I. Rennard, J. Vestbo, E. F. Wouters, P. D. Pare, R. D. Levy, H. O. Coxson, D. A. Lomas, C. P. Hersh, and E. K. Silverman. 2010. alpha-Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. *Chest* 138

Rabaiotti. 2005. Early smoking-induced lung lesions in asymptomatic subjects.

Sharp, H. L., R. A. Bridges, W. Krivit, and E. F. Freier. 1969. Cirrhosis associated with alpha-

Silva, G. E., S. Guerra, S. Keim, R. A. Barbee, and D. L. Sherrill. 2008. Longitudinal decline of

Silverman, G. A., P. I. Bird, R. W. Carrell, F. C. Church, P. B. Coughlin, P. G. Gettins, J. A.

Sivasothy, P., T. R. Dafforn, P. G. Gettins, and D. A. Lomas. 2000. Pathogenic alpha 1-

Slev, P. R., B. G. Williams, T. O. Harville, E. R. Ashwood, and J. A. Bornhorst. 2008. Efficacy

Snyder, M. R., J. A. Katzmann, M. L. Butz, C. Wiley, P. Yang, D. B. Dawson, K. C. Halling,

Sorheim, I. C., P. Bakke, A. Gulsvik, S. G. Pillai, A. Johannessen, P. I. Gaarder, E. J.

Spaggiari, E., M. Zompatori, A. Verduri, A. Chetta, C. Bna, F. Ormitti, N. Sverzellati, and E.

PiMZ alpha1-antitrypsin phenotype. *Chest* 133 (5):1095-100.

protein electrophoresis. *Am J Clin Pathol* 130 (4):568-72.

Correlations between high resolution dynamic CT and pulmonary function testing. *Radiol Med* 109 (1-2):27-39.


**10** 

*Poland* 

**The Six-Minute Walk Test on the Treadmill** 

Human physical efficiency is shaped by several factors amongst which the functional condition of the heart, lungs and arterial circulation in lower limbs are regarded to be of key importance. Several tests are applied to evaluate human physical efficiency, however, the six-minute walk test (6MWT) deserves special attention due to its usefulness and simplicity. The test builds on the patient's walking capacity, i.e. the natural physical activity. Hence, the performance of the test does not require any individual preparation. The only and at the same time simple evaluation factor in the test is the distance covered within 6 minutes on a flat area. During the six minutes, the patient adjusts the pace of the walk to his or her fatigue, dyspnoea or pain in the lower limbs. According to the recommendations formulated by the American Thoracic Association in 2002, the test should be performed in subjects with at least moderate

The six-minute walk test is used by physicians as it enables the impartial evaluation of physical efficiency and treatment effectiveness. It also plays a prognostic role in evaluating the life span of patients with heart failure. It is easy to perform the test in a hallway. However, it is difficult to compare the results of the tests in various medical centres because they are performed in hallways which differ in length. In order to overcome this limitation, ATS 2002 guidelines state that the standard length of the hallway should be 30 m and its standard width – 3 m. The hallways in some medical centres comply with the set standards for the 6-minute walk test. However, even in these centres the test cannot be performed because the hallway has been designed for internal circulation purposes. Since several centres do not have a hallway with the required length, the six-minute walk test is performed in halls of non-standard length. Hence, a situation occurs when the right ATS

The idea to circumvent the limitation resulting from various hallway lengths was brought up during a visit to a cardiac rehabilitation centre with very well equipped physical efficiency laboratories in which the patient performing the six-minute walk test disappeared behind the hallway corner changing the direction at a right angle. This rather bizarre situation gave rise to the idea of doing the six-minute walk test in optimal conditions, i.e. in a physical efficiency laboratory, on the treadmills used there. After all, it is enough to adapt the speed of the

heart failure, respiratory failure or arterial circulatory failure in lower limbs.

guidelines cannot be complied with for technical reasons.

**1. Introduction** 

Fryderyk Prochaczek1, Jacek S. Brandt1, Witold Żmuda2,

Katarzyna R. Świda1, Zbigniew W. Szczurek1, Jerzy Gałecka1 and Agnieszka Winiarska2 *1Institute of Medical Technology and Equipment, Zabrze* 

*2Clinical Cardiology, Tychy* 

leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation. *J Immunol* 183 (12):8148-56.

